Hosted on MSN3d
Novo Nordisk plans new study for CagriSema, targets 2026 submission
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
drugdeliverybusiness3d
Are over-the-counter CGMs on track to be one-hit wonders?
Diabetes device expert Steph Habif said her family's experiment with CGMs shows a big opportunity for wearables: intermittent ...
Glucotrack, Inc.: Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...
drugdeliverybusiness5d
Glucotrack completes first-in-human continuous blood glucose monitor implant study
Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...